VisiPlate
Open-Angle Glaucoma
Key Facts
About Avisi
Avisi Technologies is advancing a novel, nanotechnology-based implant called VisiPlate for the surgical treatment of open-angle glaucoma, the leading cause of irreversible blindness. The company's core innovation is an ultrathin, freestanding material fabricated using MEMS (Micro-Electro-Mechanical Systems) techniques, designed to facilitate controlled aqueous drainage with minimal foreign body response. Having secured $21.7M in total funding, including a recent $10.7M Series A round, Avisi is now conducting the pivotal SAPPHIRE clinical trial under an FDA Investigational Device Exemption (IDE). The company operates in a large and growing market with significant unmet need for more effective and tolerable surgical interventions.
View full company profileTherapeutic Areas
Other Open-Angle Glaucoma Drugs
| Drug | Company | Phase |
|---|---|---|
| MINIject® | iSTAR Medical | Pivotal Trial (US) / Post-Market (EU) |
| ViaLuxe Laser System (FLigHT Procedure) | ViaLase | Regulatory |